Subcutaneous Low-Dose Epoetin Beta for the Avoidance of Transfusion in Patients Scheduled for Elective Surgery Not Eligible for Autologous Blood Donation
This randomized, multicentre, parallel-group study assessed the efficacy of epoetin beta in reducing the transfusion frequency in patients ineligible for autologous blood donation prior to surgery. The patients (n = 194) received either epoetin beta (125 or 250 IU/kg, once weekly) or no therapy for...
Gespeichert in:
| Veröffentlicht in: | European surgical research 2001-09, Vol.33 (5-6), p.303-310 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 310 |
|---|---|
| container_issue | 5-6 |
| container_start_page | 303 |
| container_title | European surgical research |
| container_volume | 33 |
| creator | Wurnig, C. Schatz, K. Noske, H. Hemon, Y. Dahlberg, G. Josefsson, G. Milbrink, J. Hamard, Christiane |
| description | This randomized, multicentre, parallel-group study assessed the efficacy of epoetin beta in reducing the transfusion frequency in patients ineligible for autologous blood donation prior to surgery. The patients (n = 194) received either epoetin beta (125 or 250 IU/kg, once weekly) or no therapy for 3–4 weeks before surgery. The pre-operation haemoglobin levels were markedly increased in the epoetin beta groups (125 IU/kg: +1.1 g/dl; 250 IU/kg: +1.6 g/dl), but not in the control group. The transfusion frequency was significantly reduced in both epoetin groups as compared with the control group (p = 0.046). Epoetin beta was well tolerated, and no serious adverse events were observed. Low-dose administration of epoetin beta before elective surgery reduces the transfusion frequencies in patients not eligible for autologous blood donation. |
| doi_str_mv | 10.1159/000049723 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_karge</sourceid><recordid>TN_cdi_karger_primary_49723</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72412885</sourcerecordid><originalsourceid>FETCH-LOGICAL-c386t-d741991d880ba85dfbd97968639bc6e9be98522b073268a26c8461632778e31e3</originalsourceid><addsrcrecordid>eNpt0VtrFDEUAOAgil2rDz4LEpQKPoxOkrkkj9t2vcCi4lbwbcgkZ7aps8maS0t_iv_W7M7SgpiXkPDlnJNzEHpOyneE1OJ9mVclWsoeoBmpKCmEoOQhmpUlqQpG6M8j9CSEq3ysRSseoyNCeFkzLmbozyr1KkVpwaWAl-6mOHcB8GLrIBqLTyFKPDiP4yXg-bUzWloF2A34wksbhhSMszjDbzIasDHglboEnUbQ-2eLEVQ014BXya_B3-IvLuZLszb9CHsxT9GNbr3Lfjo6p_G5szmWs0_Ro0GOAZ4d9mP048Pi4uxTsfz68fPZfFkoxptY6LYiQhDNedlLXuuh1_mPDW-Y6FUDogfBa0r7smW04ZI2ilcNaRhtWw6MADtGb6a4W-9-Jwix25igYBynnnQtrQjlvM7w9T_wyiVvc20dKRtBGanrnXo7KeVdCB6GbuvNRvrbjLrdtLq7aWX78hAx9RvQ9_IwngxODkAGJcch91yZcO9YlX_Fy-xeTe6X3LX5DixW3_eZuq0eMnrxXzTV8hc757C9</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1069231555</pqid></control><display><type>article</type><title>Subcutaneous Low-Dose Epoetin Beta for the Avoidance of Transfusion in Patients Scheduled for Elective Surgery Not Eligible for Autologous Blood Donation</title><source>MEDLINE</source><source>Karger Journals</source><creator>Wurnig, C. ; Schatz, K. ; Noske, H. ; Hemon, Y. ; Dahlberg, G. ; Josefsson, G. ; Milbrink, J. ; Hamard, Christiane</creator><creatorcontrib>Wurnig, C. ; Schatz, K. ; Noske, H. ; Hemon, Y. ; Dahlberg, G. ; Josefsson, G. ; Milbrink, J. ; Hamard, Christiane ; Collaborative Study Group</creatorcontrib><description>This randomized, multicentre, parallel-group study assessed the efficacy of epoetin beta in reducing the transfusion frequency in patients ineligible for autologous blood donation prior to surgery. The patients (n = 194) received either epoetin beta (125 or 250 IU/kg, once weekly) or no therapy for 3–4 weeks before surgery. The pre-operation haemoglobin levels were markedly increased in the epoetin beta groups (125 IU/kg: +1.1 g/dl; 250 IU/kg: +1.6 g/dl), but not in the control group. The transfusion frequency was significantly reduced in both epoetin groups as compared with the control group (p = 0.046). Epoetin beta was well tolerated, and no serious adverse events were observed. Low-dose administration of epoetin beta before elective surgery reduces the transfusion frequencies in patients not eligible for autologous blood donation.</description><identifier>ISSN: 0014-312X</identifier><identifier>EISSN: 1421-9921</identifier><identifier>DOI: 10.1159/000049723</identifier><identifier>PMID: 11805389</identifier><identifier>CODEN: EUSRBM</identifier><language>eng</language><publisher>Basel, Switzerland: Karger</publisher><subject>Biological and medical sciences ; Blood Transfusion ; Blood Transfusion, Autologous ; Blood. Blood coagulation. Reticuloendothelial system ; Dose-Response Relationship, Drug ; Erythrocyte Transfusion ; Erythropoietin - administration & dosage ; Erythropoietin - therapeutic use ; Female ; Hematocrit ; Hemoglobins - analysis ; Humans ; Injections, Subcutaneous ; Iron - pharmacokinetics ; Male ; Medical sciences ; Original Paper ; Pharmacology. Drug treatments ; Postoperative Complications ; Recombinant Proteins ; Safety ; Surgical Procedures, Operative</subject><ispartof>European surgical research, 2001-09, Vol.33 (5-6), p.303-310</ispartof><rights>2001 S. Karger AG, Basel</rights><rights>2002 INIST-CNRS</rights><rights>Copyright 2001 S. Karger AG, Basel</rights><rights>Copyright (c) 2001 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c386t-d741991d880ba85dfbd97968639bc6e9be98522b073268a26c8461632778e31e3</citedby><cites>FETCH-LOGICAL-c386t-d741991d880ba85dfbd97968639bc6e9be98522b073268a26c8461632778e31e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2429,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13473280$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11805389$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wurnig, C.</creatorcontrib><creatorcontrib>Schatz, K.</creatorcontrib><creatorcontrib>Noske, H.</creatorcontrib><creatorcontrib>Hemon, Y.</creatorcontrib><creatorcontrib>Dahlberg, G.</creatorcontrib><creatorcontrib>Josefsson, G.</creatorcontrib><creatorcontrib>Milbrink, J.</creatorcontrib><creatorcontrib>Hamard, Christiane</creatorcontrib><creatorcontrib>Collaborative Study Group</creatorcontrib><title>Subcutaneous Low-Dose Epoetin Beta for the Avoidance of Transfusion in Patients Scheduled for Elective Surgery Not Eligible for Autologous Blood Donation</title><title>European surgical research</title><addtitle>Eur Surg Res</addtitle><description>This randomized, multicentre, parallel-group study assessed the efficacy of epoetin beta in reducing the transfusion frequency in patients ineligible for autologous blood donation prior to surgery. The patients (n = 194) received either epoetin beta (125 or 250 IU/kg, once weekly) or no therapy for 3–4 weeks before surgery. The pre-operation haemoglobin levels were markedly increased in the epoetin beta groups (125 IU/kg: +1.1 g/dl; 250 IU/kg: +1.6 g/dl), but not in the control group. The transfusion frequency was significantly reduced in both epoetin groups as compared with the control group (p = 0.046). Epoetin beta was well tolerated, and no serious adverse events were observed. Low-dose administration of epoetin beta before elective surgery reduces the transfusion frequencies in patients not eligible for autologous blood donation.</description><subject>Biological and medical sciences</subject><subject>Blood Transfusion</subject><subject>Blood Transfusion, Autologous</subject><subject>Blood. Blood coagulation. Reticuloendothelial system</subject><subject>Dose-Response Relationship, Drug</subject><subject>Erythrocyte Transfusion</subject><subject>Erythropoietin - administration & dosage</subject><subject>Erythropoietin - therapeutic use</subject><subject>Female</subject><subject>Hematocrit</subject><subject>Hemoglobins - analysis</subject><subject>Humans</subject><subject>Injections, Subcutaneous</subject><subject>Iron - pharmacokinetics</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Original Paper</subject><subject>Pharmacology. Drug treatments</subject><subject>Postoperative Complications</subject><subject>Recombinant Proteins</subject><subject>Safety</subject><subject>Surgical Procedures, Operative</subject><issn>0014-312X</issn><issn>1421-9921</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpt0VtrFDEUAOAgil2rDz4LEpQKPoxOkrkkj9t2vcCi4lbwbcgkZ7aps8maS0t_iv_W7M7SgpiXkPDlnJNzEHpOyneE1OJ9mVclWsoeoBmpKCmEoOQhmpUlqQpG6M8j9CSEq3ysRSseoyNCeFkzLmbozyr1KkVpwaWAl-6mOHcB8GLrIBqLTyFKPDiP4yXg-bUzWloF2A34wksbhhSMszjDbzIasDHglboEnUbQ-2eLEVQ014BXya_B3-IvLuZLszb9CHsxT9GNbr3Lfjo6p_G5szmWs0_Ro0GOAZ4d9mP048Pi4uxTsfz68fPZfFkoxptY6LYiQhDNedlLXuuh1_mPDW-Y6FUDogfBa0r7smW04ZI2ilcNaRhtWw6MADtGb6a4W-9-Jwix25igYBynnnQtrQjlvM7w9T_wyiVvc20dKRtBGanrnXo7KeVdCB6GbuvNRvrbjLrdtLq7aWX78hAx9RvQ9_IwngxODkAGJcch91yZcO9YlX_Fy-xeTe6X3LX5DixW3_eZuq0eMnrxXzTV8hc757C9</recordid><startdate>20010901</startdate><enddate>20010901</enddate><creator>Wurnig, C.</creator><creator>Schatz, K.</creator><creator>Noske, H.</creator><creator>Hemon, Y.</creator><creator>Dahlberg, G.</creator><creator>Josefsson, G.</creator><creator>Milbrink, J.</creator><creator>Hamard, Christiane</creator><general>Karger</general><general>S. Karger AG</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20010901</creationdate><title>Subcutaneous Low-Dose Epoetin Beta for the Avoidance of Transfusion in Patients Scheduled for Elective Surgery Not Eligible for Autologous Blood Donation</title><author>Wurnig, C. ; Schatz, K. ; Noske, H. ; Hemon, Y. ; Dahlberg, G. ; Josefsson, G. ; Milbrink, J. ; Hamard, Christiane</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c386t-d741991d880ba85dfbd97968639bc6e9be98522b073268a26c8461632778e31e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Biological and medical sciences</topic><topic>Blood Transfusion</topic><topic>Blood Transfusion, Autologous</topic><topic>Blood. Blood coagulation. Reticuloendothelial system</topic><topic>Dose-Response Relationship, Drug</topic><topic>Erythrocyte Transfusion</topic><topic>Erythropoietin - administration & dosage</topic><topic>Erythropoietin - therapeutic use</topic><topic>Female</topic><topic>Hematocrit</topic><topic>Hemoglobins - analysis</topic><topic>Humans</topic><topic>Injections, Subcutaneous</topic><topic>Iron - pharmacokinetics</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Original Paper</topic><topic>Pharmacology. Drug treatments</topic><topic>Postoperative Complications</topic><topic>Recombinant Proteins</topic><topic>Safety</topic><topic>Surgical Procedures, Operative</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wurnig, C.</creatorcontrib><creatorcontrib>Schatz, K.</creatorcontrib><creatorcontrib>Noske, H.</creatorcontrib><creatorcontrib>Hemon, Y.</creatorcontrib><creatorcontrib>Dahlberg, G.</creatorcontrib><creatorcontrib>Josefsson, G.</creatorcontrib><creatorcontrib>Milbrink, J.</creatorcontrib><creatorcontrib>Hamard, Christiane</creatorcontrib><creatorcontrib>Collaborative Study Group</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>European surgical research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wurnig, C.</au><au>Schatz, K.</au><au>Noske, H.</au><au>Hemon, Y.</au><au>Dahlberg, G.</au><au>Josefsson, G.</au><au>Milbrink, J.</au><au>Hamard, Christiane</au><aucorp>Collaborative Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Subcutaneous Low-Dose Epoetin Beta for the Avoidance of Transfusion in Patients Scheduled for Elective Surgery Not Eligible for Autologous Blood Donation</atitle><jtitle>European surgical research</jtitle><addtitle>Eur Surg Res</addtitle><date>2001-09-01</date><risdate>2001</risdate><volume>33</volume><issue>5-6</issue><spage>303</spage><epage>310</epage><pages>303-310</pages><issn>0014-312X</issn><eissn>1421-9921</eissn><coden>EUSRBM</coden><abstract>This randomized, multicentre, parallel-group study assessed the efficacy of epoetin beta in reducing the transfusion frequency in patients ineligible for autologous blood donation prior to surgery. The patients (n = 194) received either epoetin beta (125 or 250 IU/kg, once weekly) or no therapy for 3–4 weeks before surgery. The pre-operation haemoglobin levels were markedly increased in the epoetin beta groups (125 IU/kg: +1.1 g/dl; 250 IU/kg: +1.6 g/dl), but not in the control group. The transfusion frequency was significantly reduced in both epoetin groups as compared with the control group (p = 0.046). Epoetin beta was well tolerated, and no serious adverse events were observed. Low-dose administration of epoetin beta before elective surgery reduces the transfusion frequencies in patients not eligible for autologous blood donation.</abstract><cop>Basel, Switzerland</cop><pub>Karger</pub><pmid>11805389</pmid><doi>10.1159/000049723</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0014-312X |
| ispartof | European surgical research, 2001-09, Vol.33 (5-6), p.303-310 |
| issn | 0014-312X 1421-9921 |
| language | eng |
| recordid | cdi_karger_primary_49723 |
| source | MEDLINE; Karger Journals |
| subjects | Biological and medical sciences Blood Transfusion Blood Transfusion, Autologous Blood. Blood coagulation. Reticuloendothelial system Dose-Response Relationship, Drug Erythrocyte Transfusion Erythropoietin - administration & dosage Erythropoietin - therapeutic use Female Hematocrit Hemoglobins - analysis Humans Injections, Subcutaneous Iron - pharmacokinetics Male Medical sciences Original Paper Pharmacology. Drug treatments Postoperative Complications Recombinant Proteins Safety Surgical Procedures, Operative |
| title | Subcutaneous Low-Dose Epoetin Beta for the Avoidance of Transfusion in Patients Scheduled for Elective Surgery Not Eligible for Autologous Blood Donation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T20%3A36%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_karge&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Subcutaneous%20Low-Dose%20Epoetin%20Beta%20for%20the%20Avoidance%20of%20Transfusion%20in%20Patients%20Scheduled%20for%20Elective%20Surgery%20Not%20Eligible%20for%20Autologous%20Blood%20Donation&rft.jtitle=European%20surgical%20research&rft.au=Wurnig,%20C.&rft.aucorp=Collaborative%20Study%20Group&rft.date=2001-09-01&rft.volume=33&rft.issue=5-6&rft.spage=303&rft.epage=310&rft.pages=303-310&rft.issn=0014-312X&rft.eissn=1421-9921&rft.coden=EUSRBM&rft_id=info:doi/10.1159/000049723&rft_dat=%3Cproquest_karge%3E72412885%3C/proquest_karge%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1069231555&rft_id=info:pmid/11805389&rfr_iscdi=true |